ACH
DYN icon

ArrowMark Colorado Holdings’s Dyne Therapeutics DYN Stock Holding History

ArrowMark Colorado Holdings’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.82M Sell
397,221
-276,728
-41% -$5.14M 0.37% 104
2026
Q1 		$12.2M Sell
673,949
-26,704
-4% -$460K 0.32% 92
2025
Q4 		$13.7M Sell
700,653
-85,262
-11% -$1.61M 0.3% 99
2025
Q3 		$9.94M Buy
785,915
+15,690
+2% +$179K 0.18% 136
2025
Q2 		$7.33M Sell
770,225
-127,721
-14% -$1.41M 0.13% 159
2025
Q1 		$9.39M Sell
897,946
-34,285
-4% -$490K 0.15% 130
2024
Q4 		$22M Buy
932,231
+32,041
+4% +$948K 0.3% 89
2024
Q3 		$32.3M Sell
900,190
-19,226
-2% -$765K 0.41% 69
2024
Q2 		$32.4M Buy
919,416
+537,000
+140% +$15.6M 0.39% 73
2024
Q1 		$10.9M Hold
382,416
– – 0.12% 137
2023
Q4 		$5.09M Hold
382,416
– – 0.06% 203
2023
Q3 		$3.43M Hold
382,416
– – 0.04% 210
2023
Q2 		$4.3M Buy
382,416
+107,252
+39% +$1.27M 0.05% 207
2023
Q1 		$3.17M Hold
275,164
– – 0.04% 214
2022
Q4 		$3.19M Hold
275,164
– – 0.04% 216
2022
Q3 		$3.5M Buy
275,164
+106,664
+63% +$1.22M 0.04% 232
2022
Q2 		$1.16M Hold
168,500
– – 0.01% 262
2022
Q1 		$1.62M Hold
168,500
– – 0.01% 275
2021
Q4 		$2M Hold
168,500
– – 0.02% 269
2021
Q3 		$2.74M Hold
168,500
– – 0.02% 273
2021
Q2 		$3.54M Buy
168,500
+68,500
+69% +$1.29M 0.03% 257
2021
Q1 		$1.55M Hold
100,000
– – 0.01% 289
2020
Q4 		$2.1M Sell
100,000
-100,000
-50% -$1.98M 0.02% 263
2020
Q3 		$4.04M Buy
+200,000
New +$4.39M 0.04% 229

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

ArrowMark Colorado Holdings's DYN Position: Q2 2026 in Review

ArrowMark Colorado Holdings reduced its Dyne Therapeutics (DYN) stake by 41% in Q2 2026, selling an estimated $5.14M and leaving 397,221 shares worth $8.82M. The position accounts for 0.37% of the portfolio, ranked #104.

ArrowMark Colorado Holdings first reported a position in DYN in Q3 2020 and has held it in 24 quarters since. The position peaked at $32.4M in Q2 2024. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • ArrowMark Colorado Holdings held 397,221 shares of Dyne Therapeutics worth $8.82M as of Q2 2026.
  • ArrowMark Colorado Holdings sold 276,728 Dyne Therapeutics shares in Q2 2026, an estimated $5.14M.
  • Dyne Therapeutics made up 0.37% of ArrowMark Colorado Holdings's portfolio in Q2 2026, its #104 holding.
  • ArrowMark Colorado Holdings first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • ArrowMark Colorado Holdings's Dyne Therapeutics position peaked at $32.4M in Q2 2024.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.